## Mar?a Gaibar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9039547/publications.pdf

Version: 2024-02-01

1163117 1058476 19 226 8 14 citations h-index g-index papers 20 20 20 354 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. PLoS ONE, 2015, 10, e0132269.	2.5	37
2	Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients. PLoS ONE, 2013, 8, e70183.	2.5	37
3	Somatic Mutations in <i>HER2</i> and Implications for Current Treatment Paradigms in <i>HER2</i> -Positive Breast Cancer. Journal of Oncology, 2020, 2020, 1-13.	1.3	35
4	STR genetic diversity in a Mediterranean population from the south of the Iberian Peninsula. Annals of Human Biology, 2010, 37, 254-267.	1.0	18
5	Usefulness of autosomal STR polymorphisms beyond forensic purposes: data on Arabic- and Berber-speaking populations from central Morocco. Annals of Human Biology, 2012, 39, 297-304.	1.0	12
6	Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer. Frontiers in Oncology, 2021, 11, 633233.	2.8	12
7	Cytochrome and sulfotransferase gene variation in north African populations. Pharmacogenomics, 2016, 17, 1415-1423.	1.3	10
8	Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World Journal of Gastroenterology, 2020, 26, 1979-1986.	3.3	9
9	Genetic differences among North African Berber and Arab-speaking populations revealed by Y-STR diversity. Annals of Human Biology, 2011, 38, 228-236.	1.0	8
10	Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia. International Journal of Biological Markers, 2015, 30, 148-151.	1.8	7
11	Pharmacogenetics of ugt genes in North African populations. Pharmacogenomics Journal, 2018, 18, 609-612.	2.0	7
12	Polymorphisms influencing muscle phenotypes in North-African and Spanish populations. Annals of Human Biology, 2012, 39, 166-169.	1.0	6
13	Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene. Pharmacogenomics Journal, 2017, 17, 109-111.	2.0	5
14	Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 1381.	4.1	5
15	UDP-glucuronosyltransferase genetic variation in North African populations: a comparison with African and European data. Annals of Human Biology, 2018, 45, 516-523.	1.0	4
16	miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1263-1273.	0.7	4
17	FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer. Pharmaceutics, 2022, 14, 242.	4.5	4
18	Tamoxifen Therapy in Breast Cancer: Do Apolipoprotein E Genotype and Menopausal State Affect Plasma Lipid Changes Induced by the Drug?. International Journal of Biological Markers, 2013, 28, 371-376.	1.8	3

#	Article	IF	CITATIONS
19	Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types. Oncology Letters, 2018, 16, 6950-6959.	1.8	3